Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Stomach Neoplasms 3Breast Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Hematologic Neoplasms 1HER2-positive Breast Cancer 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Metastatic 1

Interventions

Trastuzumab 3Docetaxel 3Gemcitabine 2tusamitamab ravtansine 1nirogacestat 1margetuximab 1exemestane 1Vinorelbine 1Tamoxifen 1Letrozole 1Fulvestrant 1Capecitabine 1Anastrozole 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Breast Cancer Metastatic × margetuximab × Clear all
NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Zai Lab (Hong Kong), Ltd.

Phase 2 Unknown
123 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡